Exploring the Evolution and Efficacy of Targeted Therapy in Modern Oncology
OthersPage Navigation
Introduction
Over the past decades, the field of oncology has witnessed a significant shift from conventional, non-specific chemotherapies to more precise, molecularly targeted therapies.
Evolution of Targeted Therapies
Targeted therapies emerged from the understanding of cancer's molecular basis. The first-generation targeted drugs, such as imatinib, offered a glimpse into the potential of this approach. The landscape has evolved with advancements in genomics and bioinformatics, leading to the development of next-generation targeted therapies.
Efficacy of Targeted Therapies
The efficacy of targeted therapies is evident in their ability to improve patient outcomes. These therapies offer a personalized approach, targeting specific mutations in individual patients, thereby reducing side effects and improving response rates. However, challenges such as drug resistance remain.
Conclusion
Despite challenges, the evolution and efficacy of targeted therapies have revolutionized oncology, offering a more personalized and effective approach to cancer treatment. As our understanding of cancer's molecular complexities expands, so too will the potential of targeted therapies.
Recommended News For You
Recommended Articles For You
Featured News
Featured Articles
Featured Events
Featured KOL Videos
1.
New guidelines for radiation therapy for HPV-associated head and neck cancer
2.
Cancer mortality continuing to decline, says report
3.
Getting Lung Cancer Screening Staff Involved Improved Tobacco Cessation
4.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
5.
Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control
1.
Different Types of Blood Dyscrasias
2.
Pembrolizumab Plus Lenvatinib in EBV-Associated Advanced Intrahepatic Cholangiocarcinoma: Case Study
3.
Lymphomatoid Papulosis: What You Need to Know
4.
MASLD and Cancer Risk: Pathogenic Links and Clinical Implications Reviewed
5.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Clinical Insights in Oncology
2.
INO-VATE: The Long-Term Overall Survival Analysis in Iontuzumab-Treated Patients
3.
Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion
4.
Navigating the Complexities of Ph Negative ALL - Part XI
5.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Welcome to Hidoc Dr.
Join to enhance your clinical skills and gain specialized in-depth medical knowledge